Metraipolis › archive › dc_763eda4e2c20
ALTO-203 — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/ALTO-203
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-07T00:19:46.718Z
- SHA-256 of the archived text
83fc955a9dc17ed359316bdb17648b522f1eeb70954a921c38332190d9c4a517- Stable URL of this page
https://metraipolis.com/documento/dc_763eda4e2c20
How to cite
ALTO-203 — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/ALTO-203 (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_763eda4e2c20 (Metraipolis archive dc_763eda4e2c20, sha256 83fc955a9dc17ed359316bdb17648b522f1eeb70954a921c38332190d9c4a517)
BibTeX
@misc{dc763eda4e2c20,
title = {ALTO-203 — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/ALTO-203},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_763eda4e2c20; sha256 83fc955a9dc17ed359316bdb17648b522f1eeb70954a921c38332190d9c4a517},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/ALTO-203. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
ALTO-203 is a histamine H3 receptor inverse agonist which is under development for the treatment of major depressive disorder with anhedonia. It was also under development for other psychiatric disorders and neurodegenerative disorders, but development for these indications was discontinued. The drug is taken orally. It has been found to increase dopamine release in the nucleus accumbens and produce antianhedonic-like effects in rodents, effects which another histamine H3 receptor inverse agonist, pitolisant, did not produce. ALTO-203 is under development by Alto Neuroscience. As of July 2025, it is in phase 2 clinical trials for major depressive disorder. In a phase 1 trial, ALTO-203 was reported to increase subjective positive mood to a similar degree as modafinil. On the other hand, the drug failed to meet its primary endpoint, a measure of mood and alertness, compared to placebo in a phase 2 trial. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «ALTO-203» — https://en.wikipedia.org/wiki/ALTO-203 Wikidata Q140288875: «pharmaceutical compound» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q140288875 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/ALTO-203?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1372015276, consultata il 2026-11-07T00:16:05.668Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: f912f642dd94d8cac4e21b094378101c694895e18621bb23fd2dd2f8f0539467